John M. Burke, MD, Rocky Mountain Cancer Centers

BTK Inhibitors in Relapsed/Refractory CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

MURANO Trial Update in R/R CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Utility of MRD Testing in CLL Management

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Venetoclax Combinations, Safety and Efficacy

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Venetoclax and Obinutuzumab in CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Novel Therapies for Relapsed/Refractory CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Relapsed/Refractory CLL: Treatment Selection

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

BTK inhibitor With vs Without a CD20-Targeted Antibody

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Second-Generation BTK Inhibitors in CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Therapies in the Pipeline for Frontline CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Telemedicine for Patients With CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

BTK Inhibitors in CLL: Ibrutinib

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Current Role for Chemoimmunotherapy in CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Treating CLL During COVID-19

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Frontline Treatment Options in CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Selecting Frontline Therapy for CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

COVID-19 and CLL Treatment Initiation

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Selecting First-Line Therapy for CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Advances in Frontline Therapy for CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Impact of COVID-19 on Management of CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Initial Work-up for Chronic Lymphocytic Leukemia

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Articles by John M. Burke, MD, Rocky Mountain Cancer Centers

BTK Inhibitors in Relapsed/Refractory CLL

MURANO Trial Update in R/R CLL

Utility of MRD Testing in CLL Management

Venetoclax Combinations, Safety and Efficacy

Venetoclax and Obinutuzumab in CLL

Novel Therapies for Relapsed/Refractory CLL

Relapsed/Refractory CLL: Treatment Selection

BTK inhibitor With vs Without a CD20-Targeted Antibody

Second-Generation BTK Inhibitors in CLL

Therapies in the Pipeline for Frontline CLL

Telemedicine for Patients With CLL

BTK Inhibitors in CLL: Ibrutinib

Current Role for Chemoimmunotherapy in CLL

Treating CLL During COVID-19

Frontline Treatment Options in CLL

Selecting Frontline Therapy for CLL

COVID-19 and CLL Treatment Initiation

Selecting First-Line Therapy for CLL

Advances in Frontline Therapy for CLL

Impact of COVID-19 on Management of CLL

Initial Work-up for Chronic Lymphocytic Leukemia

Trending on OncLive

Domvanalimab/Zimberelimab Plus Chemotherapy Fails to Improve OS in HER2-Negative Gastroesophageal Adenocarcinoma

Extended FOLFOX, Atezolizumab Duration Linked With Improved DFS in Stage III dMMR Colon Cancer

Bexobrutideg Could Pave the Way for BTK Degraders in R/R Chronic Lymphocytic Leukemia

AI Finds New Applications in Oncologic Surgery, Drug and Biomarker Screening, and Clinical Trial Design

ESR1 Mutations Steer the Oral SERD Story in Breast Cancer: With Sara Nunnery, MD, MSCI; and MinhTri Nguyen, MD